PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 22653811-8 2012 We demonstrate that (1) hepatocytes can be efficiently generated from FH iPSCs; (2) in contrast to control cells, FH iPSC-derived hepatocytes are deficient in LDL-C uptake; (3) control but not FH iPSC-derived hepatocytes increase LDL uptake in response to lovastatin; and (4) FH iPSC-derived hepatocytes display a marked elevation in secretion of lipidated apolipoprotein B-100. Lovastatin 256-266 low density lipoprotein receptor Homo sapiens 114-116 22653811-8 2012 We demonstrate that (1) hepatocytes can be efficiently generated from FH iPSCs; (2) in contrast to control cells, FH iPSC-derived hepatocytes are deficient in LDL-C uptake; (3) control but not FH iPSC-derived hepatocytes increase LDL uptake in response to lovastatin; and (4) FH iPSC-derived hepatocytes display a marked elevation in secretion of lipidated apolipoprotein B-100. Lovastatin 256-266 low density lipoprotein receptor Homo sapiens 114-116 22653811-8 2012 We demonstrate that (1) hepatocytes can be efficiently generated from FH iPSCs; (2) in contrast to control cells, FH iPSC-derived hepatocytes are deficient in LDL-C uptake; (3) control but not FH iPSC-derived hepatocytes increase LDL uptake in response to lovastatin; and (4) FH iPSC-derived hepatocytes display a marked elevation in secretion of lipidated apolipoprotein B-100. Lovastatin 256-266 low density lipoprotein receptor Homo sapiens 114-116 15025528-10 2004 Treatment of the cells with Lovastatin, which inhibits HMG-Co reductase and increases expression of LDL receptor, stimulates luciferase expression, suggesting that the gene delivery is specifically mediated by LDL receptor. Lovastatin 28-38 low density lipoprotein receptor Homo sapiens 100-112 21994451-5 2011 Cell exposure to chlorpromazine, an inhibitor of the clathrin-mediated pathway used by the low-density lipoprotein receptor for endocytosis, also impacted the cholesterol level; however, this level of inhibition was not achievable when the synthesis inhibitor lovastatin was used. Lovastatin 260-270 low density lipoprotein receptor Homo sapiens 91-123 21118482-0 2010 Synergic effect of eicosapentaenoic acid and lovastatin on gene expression of HMGCoA reductase and LDL receptor in cultured HepG2 cells. Lovastatin 45-55 low density lipoprotein receptor Homo sapiens 99-111 21118482-4 2010 The purpose of this study was to investigate whether combined treatment with Eicosapentaenoic acid (EPA) and lovastatin enhanced the regulatory effect on gene expression of HMGCoA reductase and LDL receptor in HepG2 cell line. Lovastatin 109-119 low density lipoprotein receptor Homo sapiens 194-206 21118482-5 2010 RESULTS: The combined treatment with EPA and lovastatin enhanced the regulatory effect on gene expression of HMGCoA reductase and LDL receptor in HepG2 cell line. Lovastatin 45-55 low density lipoprotein receptor Homo sapiens 130-142 20459026-9 2010 Cellular cholesterol was decreased and the expression of SREBP-2 and LDLR were up-regulated by Lovastatin. Lovastatin 95-105 low density lipoprotein receptor Homo sapiens 69-73 18266936-7 2008 Collectively, these data report that lovastatin mediates inhibition of LDLR distribution and beta-cleavage of APP in a geranylgeranyl-pyrophosphate and endocytosis-dependent manner. Lovastatin 37-47 low density lipoprotein receptor Homo sapiens 71-75 15485695-0 2004 Synergistic upregulation of low-density lipoprotein receptor activity by tamoxifen and lovastatin. Lovastatin 87-97 low density lipoprotein receptor Homo sapiens 28-60 18266936-3 2008 In this study, we report that lovastatin treatment reduced Abeta output in cultured hippocampal neurons as a result of reduced APP levels and beta-secretase activities in low density Lubrol WX (non-ionic detergent) extractable lipid rafts (LDLR). Lovastatin 30-40 low density lipoprotein receptor Homo sapiens 240-244 15485695-6 2004 When studied in combination, especially at relatively high LDL concentrations in the medium, tamoxifen and lovastatin stimulated LDL receptor activity synergistically, which is attributed to the different mechanism of action these drugs exhibit. Lovastatin 107-117 low density lipoprotein receptor Homo sapiens 129-141 15025528-10 2004 Treatment of the cells with Lovastatin, which inhibits HMG-Co reductase and increases expression of LDL receptor, stimulates luciferase expression, suggesting that the gene delivery is specifically mediated by LDL receptor. Lovastatin 28-38 low density lipoprotein receptor Homo sapiens 210-222 12208479-10 2002 These results demonstrate that inhibition of cholesterol biosynthesis by lovastatin and simvastatin modifies the normal diurnal rhythm of cholesterol biosynthesis in female FH patients. Lovastatin 73-83 low density lipoprotein receptor Homo sapiens 173-175 11728391-3 2001 Atorvastatin and lovastatin increased low-density lipoprotein receptor mRNA (2.5-fold at 3 x 10(-7) M) and the transcription rate at the promoter of the low-density lipoprotein receptor gene (>5-fold at 10(-6) M). Lovastatin 17-27 low density lipoprotein receptor Homo sapiens 38-70 11728391-3 2001 Atorvastatin and lovastatin increased low-density lipoprotein receptor mRNA (2.5-fold at 3 x 10(-7) M) and the transcription rate at the promoter of the low-density lipoprotein receptor gene (>5-fold at 10(-6) M). Lovastatin 17-27 low density lipoprotein receptor Homo sapiens 153-185 9555954-8 1998 The results demonstrate three important outcomes of lovastatin treatment in these subjects: LDL receptor activity increased by 49% (P < 0.02); LDL apoB production rate decreased by 17% (P < 0.03), and LDL particle in vivo affinity for the LDL receptor decreased by 15% (P < 0.01). Lovastatin 52-62 low density lipoprotein receptor Homo sapiens 92-104 9678770-5 1998 Lovastatin supplementation of the atherogenic diet induced significant upregulation of both LDL receptor and HMG CoA reductase message levels in liver and intestine compared to the chow and atherogenic diet fed groups. Lovastatin 0-10 low density lipoprotein receptor Homo sapiens 92-104 9678770-6 1998 These data demonstrate that lovastatin supplementation of an atherogenic diet decreases foam cell accumulation and induces upregulation of hepatic and intestinal LDL receptor and HMG CoA reductase mRNA levels. Lovastatin 28-38 low density lipoprotein receptor Homo sapiens 162-174 9555954-8 1998 The results demonstrate three important outcomes of lovastatin treatment in these subjects: LDL receptor activity increased by 49% (P < 0.02); LDL apoB production rate decreased by 17% (P < 0.03), and LDL particle in vivo affinity for the LDL receptor decreased by 15% (P < 0.01). Lovastatin 52-62 low density lipoprotein receptor Homo sapiens 245-257 9199267-8 1997 LDL and lovastatin modulated the LDL-R expression without affecting SI. Lovastatin 8-18 low density lipoprotein receptor Homo sapiens 33-38 1986017-7 1991 When the twins were treated with lovastatin, however, FCRs for LDL increased significantly, suggesting enhancement of LDL receptor activity. Lovastatin 33-43 low density lipoprotein receptor Homo sapiens 118-130 8765518-3 1996 Mevinolin (lovastatin) was found to increase the LDL receptor expression by 70% at the same concentration. Lovastatin 0-9 low density lipoprotein receptor Homo sapiens 49-61 8765518-3 1996 Mevinolin (lovastatin) was found to increase the LDL receptor expression by 70% at the same concentration. Lovastatin 11-21 low density lipoprotein receptor Homo sapiens 49-61 7728297-7 1994 In contrast, lovastatin, at concentrations of 0.25 mumol/l, increased the LDL receptor activity in both control lymphocytes and lymphocytes from patients with familial hypercholesterolemia by 121% and 148%, respectively. Lovastatin 13-23 low density lipoprotein receptor Homo sapiens 74-86 8263421-9 1993 This study also provides direct proof that lovastatin, a drug that enhances LDL receptor activity in the liver, also increases the hepatic uptake of LDL in humans. Lovastatin 43-53 low density lipoprotein receptor Homo sapiens 76-88 8385478-4 1993 All VLDL subspecies bound to the LDL receptor of cultured human fibroblasts with similar, high affinities on both placebo and lovastatin, but VLDL Sf 100-400 and VLDL Sf 60-100 caused less suppression of 3-hydroxy-3-methyl glutaryl coenzyme A reductase activity after lovastatin therapy, indicating reduced LDL receptor-mediated cholesterol delivery. Lovastatin 126-136 low density lipoprotein receptor Homo sapiens 33-45 1431581-8 1992 Lovastatin therapy in CESD appears to be clinically beneficial and has complex effects on lipid metabolism that may include a dominant inhibitory effect on hepatic lipoprotein production, posttranscriptionally mediated induction of the LDL receptor, and alterations of LDL particles that interfere with their clearance by the LDL receptor in vivo. Lovastatin 0-10 low density lipoprotein receptor Homo sapiens 236-248 1431581-8 1992 Lovastatin therapy in CESD appears to be clinically beneficial and has complex effects on lipid metabolism that may include a dominant inhibitory effect on hepatic lipoprotein production, posttranscriptionally mediated induction of the LDL receptor, and alterations of LDL particles that interfere with their clearance by the LDL receptor in vivo. Lovastatin 0-10 low density lipoprotein receptor Homo sapiens 326-338 1919427-6 1991 These results strongly suggest that an increase in LDL-receptor activity is the major mechanism whereby LDL levels are lowered during lovastatin therapy. Lovastatin 134-144 low density lipoprotein receptor Homo sapiens 51-63 8663292-4 1996 Up-regulation of LDL receptors by lovastatin treatment of normal human foreskin fibroblasts (FSF cells) resulted in an increase in LPL-induced VLDL binding and catabolism to a level that was 10-15-fold greater than in LDL receptor-negative fibroblasts, despite similar LRP activity in both cell lines. Lovastatin 34-44 low density lipoprotein receptor Homo sapiens 17-29 8800498-5 1996 We studied mRNA levels of the LDL-R and HMG CoA reductase genes in response to the HMG CoA reductase inhibitor lovastatin in a time- and dose-dependent fashion in cultured human skin fibroblasts and we devised an in vitro model to study the response to drug therapy in subjects with FH. Lovastatin 111-121 low density lipoprotein receptor Homo sapiens 30-35 8800498-8 1996 Control subjects exhibited coordinate regulation of the LDL-R and HMG CoA reductase genes in response to lovastatin, 0.1-25 microM, for 0-24 h. Correlation coefficients between mRNA levels of both genes were > 0.9 in controls and FH subjects. Lovastatin 105-115 low density lipoprotein receptor Homo sapiens 56-61 8800498-13 1996 Some subjects, with FH caused by the > 10-kb deletion of the LDL-R gene, who fail to respond to HMG CoA reductase inhibitors have abnormal LDL receptor binding activity at the cell surface in response to lovastatin in vitro. Lovastatin 207-217 low density lipoprotein receptor Homo sapiens 64-69 8800498-13 1996 Some subjects, with FH caused by the > 10-kb deletion of the LDL-R gene, who fail to respond to HMG CoA reductase inhibitors have abnormal LDL receptor binding activity at the cell surface in response to lovastatin in vitro. Lovastatin 207-217 low density lipoprotein receptor Homo sapiens 142-154 8628597-5 1996 Therefore, our objectives were to determine the efficacy, safety, and tolerance of the short-term use of lovastatin, a 3-hydroxy 3-methylglutaryl coenzyme A reductase inhibitor, in the control of severe FH in a male pediatric population and to evaluate the dose-response relationship. Lovastatin 105-115 low density lipoprotein receptor Homo sapiens 203-205 8719939-0 1995 Is responsiveness to lovastatin in familial hypercholesterolaemia heterozygotes influenced by the specific mutation in the low-density lipoprotein receptor gene? Lovastatin 21-31 low density lipoprotein receptor Homo sapiens 123-155 8295321-15 1994 Thus, a low dose of lovastatin appears highly effective for treatment of moderate hypercholesterolemia in most postmenopausal women, presumably because it reverses the reduction in LDL receptor activity associated with menopause. Lovastatin 20-30 low density lipoprotein receptor Homo sapiens 181-193 8345800-0 1993 The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism. Lovastatin 16-26 low density lipoprotein receptor Homo sapiens 67-96 2176080-9 1990 A similar induction of HMG-CoA reductase and LDL receptor was also found after preincubations of cells with 0.3 microM-mevinolin, suggesting that the underlying mechanism for this induction is identical for both drugs. Lovastatin 119-128 low density lipoprotein receptor Homo sapiens 45-57 2086705-5 1990 It was unlikely that the increase in LDL receptor mRNA levels observed in mitogen-stimulated cells related merely to sterol deprivation since suppression of endogenous cholesterol synthesis with lovastatin increased LDL receptor mRNA only modestly. Lovastatin 195-205 low density lipoprotein receptor Homo sapiens 216-228 2394831-12 1990 In the new steady state that exists during long-term lovastatin therapy, along with increased expression of the genes for HMG-CoA reductase and the LDL receptor, the body compensates for the effects of the drug so that cholesterol production rate and tissue pool sizes are not changed from pretreatment values. Lovastatin 53-63 low density lipoprotein receptor Homo sapiens 148-160 2310768-4 1990 PHA enhanced 125I-labelled LDL receptor-mediated binding by lymphocytes cultured in lipoprotein-deficient medium over a 4 day period and mevinolin augmented the effect. Lovastatin 137-146 low density lipoprotein receptor Homo sapiens 27-39 2360916-0 1990 Effects of lovastatin therapy on LDL receptor activity in circulating monocytes and on structure and composition of plasma lipoproteins. Lovastatin 11-21 low density lipoprotein receptor Homo sapiens 33-45 2360916-1 1990 The effect of lovastatin therapy on LDL-receptor activity in fresh monocytes and on the structure and composition of lipoproteins was determined in 9 patients with familial hypercholesterolemia (FH) and 8 patients with non-familial hypercholesterolemia (NFH). Lovastatin 14-24 low density lipoprotein receptor Homo sapiens 36-48 2360916-7 1990 The investigations thus demonstrated that lovastatin therapy is associated with a measurable and significant increase of LDL-receptor activity in circulating monocytes that may contribute to the lipid lowering action of the drug. Lovastatin 42-52 low density lipoprotein receptor Homo sapiens 121-133 2299987-0 1990 The influence of apolipoprotein E phenotype on the response to lovastatin therapy in patients with heterozygous familial hypercholesterolemia. Lovastatin 63-73 low density lipoprotein receptor Homo sapiens 112-141 25395200-2 2015 We assessed the effect of tamoxifen, raloxifene and toremifene and their combinations with lovastatin on LDL receptor activity in lymphocytes from normolipidaemic and familial hypercholesterolaemic (FH) subjects, and human HepG2 hepatocytes and MOLT-4 lymphoblasts. Lovastatin 91-101 low density lipoprotein receptor Homo sapiens 105-117 25395200-11 2015 There is a mild enhancement between SERMs and lovastatin of lymphocyte LDLR activity, the potentiation being greater in HepG2 and MOLT-4 cells. Lovastatin 46-56 low density lipoprotein receptor Homo sapiens 71-75 2725293-6 1989 Similar decreases in urinary mevalonate excretions were observed when patients with FH were treated directly with 40 mg (20 mg twice daily) or 80 mg (40 mg twice daily) mg of lovastatin daily. Lovastatin 175-185 low density lipoprotein receptor Homo sapiens 84-86 2912432-8 1989 Patients with heterozygous FH respond to therapy with mevinolin and a bile-acid-binding resin by lowering plasma cholesterol levels. Lovastatin 54-63 low density lipoprotein receptor Homo sapiens 27-29 6569064-0 1984 Hypocholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia. Lovastatin 31-40 low density lipoprotein receptor Homo sapiens 71-100 6569064-1 1984 We have evaluated the hypolipidemic effects of mevinolin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, the rate-limiting enzyme in cholesterol biosynthesis in 13 patients with heterozygous familial hypercholesterolemia (FH). Lovastatin 47-56 low density lipoprotein receptor Homo sapiens 220-249 6569064-1 1984 We have evaluated the hypolipidemic effects of mevinolin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, the rate-limiting enzyme in cholesterol biosynthesis in 13 patients with heterozygous familial hypercholesterolemia (FH). Lovastatin 47-56 low density lipoprotein receptor Homo sapiens 251-253 6569064-7 1984 These results indicate that mevinolin is an effective hypolipidemic agent in patients with heterozygous FH but that the optimal doses in these patients are greater than those previously reported in normal volunteers. Lovastatin 28-37 low density lipoprotein receptor Homo sapiens 104-106 6569064-8 1984 If long-term safety can be satisfactorily established, mevinolin offers considerable promise in the therapy of heterozygous FH. Lovastatin 55-64 low density lipoprotein receptor Homo sapiens 124-126 6087838-3 1984 Furthermore, this increased LDL receptor activity in cells incubated for 24 h with mevinolin and lipoprotein-depleted serum (LPDS) led to a nearly 3-fold increase in the formation of cholesteryl esters when these cells were then incubated with LDL for 24 h. Continuous exposure to mevinolin did not result in a constant increase in LDL receptor activity. Lovastatin 83-92 low density lipoprotein receptor Homo sapiens 28-40 6087838-3 1984 Furthermore, this increased LDL receptor activity in cells incubated for 24 h with mevinolin and lipoprotein-depleted serum (LPDS) led to a nearly 3-fold increase in the formation of cholesteryl esters when these cells were then incubated with LDL for 24 h. Continuous exposure to mevinolin did not result in a constant increase in LDL receptor activity. Lovastatin 83-92 low density lipoprotein receptor Homo sapiens 332-344 6087838-3 1984 Furthermore, this increased LDL receptor activity in cells incubated for 24 h with mevinolin and lipoprotein-depleted serum (LPDS) led to a nearly 3-fold increase in the formation of cholesteryl esters when these cells were then incubated with LDL for 24 h. Continuous exposure to mevinolin did not result in a constant increase in LDL receptor activity. Lovastatin 281-290 low density lipoprotein receptor Homo sapiens 28-40 6087838-4 1984 Cells exposed to mevinolin for 24 h on day 3 had increased LDL receptor activity, but continuous exposure to mevinolin with 5% human serum (HS) from day 3-9 resulted in degradation of [125I]LDL at the same rate as observed in cells incubated with 5% HS alone. Lovastatin 17-26 low density lipoprotein receptor Homo sapiens 59-71 2552800-9 1989 These results provide direct evidence that therapy with lovastatin and a bile acid-binding resin can lead to increased expression of functional LDL receptors by lymphocytes in the majority (eight of 12) of patients with heterozygous FH. Lovastatin 56-66 low density lipoprotein receptor Homo sapiens 233-235 2741883-9 1989 The advent of lovastatin and other HMG COA reductase inhibitors is likely to decrease the use of partial ileal bypass to treat familial hypercholesterolemia. Lovastatin 14-24 low density lipoprotein receptor Homo sapiens 127-156 2725293-0 1989 Reduction in plasma low-density lipoprotein cholesterol and urinary mevalonic acid by lovastatin in patients with heterozygous familial hypercholesterolemia. Lovastatin 86-96 low density lipoprotein receptor Homo sapiens 127-156 3029155-9 1987 These results suggest that treatment of patients with defects in the LDL receptor pathway with mevinolin improves the plasma lipid profile and does not result in adrenal dysfunction or further exacerbation of the mild impairment of adrenal function during maximal ACTH stimulation. Lovastatin 95-104 low density lipoprotein receptor Homo sapiens 69-81 28802576-0 2017 Atorvastatin and lovastatin, but not pravastatin, increased cellular complex formation between PCSK9 and the LDL receptor in human hepatocyte-like C3A cells. Lovastatin 17-27 low density lipoprotein receptor Homo sapiens 109-121